2002

Renal Anemia

Conflicts and Controversies

Editors:

ISBN: 978-90-481-6045-7 (Print) 978-94-015-9998-6 (Online)

Table of contents (15 chapters)

  1. Front Matter

    Pages i-xi

  2. No Access

    Book Chapter

    Pages 1-7

    Correcting anemia slows renal disease progression

  3. No Access

    Book Chapter

    Pages 9-13

    Does treatment with EPO improve RBC survival?

  4. No Access

    Book Chapter

    Pages 15-28

    Has the best route of administration for epoetin been established?

  5. No Access

    Book Chapter

    Pages 29-35

    Is renal anemia management determined by science or reimbursement regulations?

  6. No Access

    Book Chapter

    Pages 37-47

    When does anemia impact the heart in chronic kidney disease?

  7. No Access

    Book Chapter

    Pages 49-64

    Improvements in anemia management with darbepoetin alfa, a new erythropoiesis stimulating protein

  8. No Access

    Book Chapter

    Pages 65-80

    Normalizing hematocrit in renal failure: dangerous or desirable?

  9. No Access

    Book Chapter

    Pages 81-88

    Do race, gender or mode of dialysis modulate erythropoietin response?

  10. No Access

    Book Chapter

    Pages 89-98

    Are uremic inhibitors of erythropoiesis clinically relevant?

  11. No Access

    Book Chapter

    Pages 99-106

    Do ACE inhibitors limit response to EPO and should EPO be continued in patients with sepsis or fever?

  12. No Access

    Book Chapter

    Pages 107-113

    Is secondary hyperparathyroidism a significant cause of renal anemia?

  13. No Access

    Book Chapter

    Pages 115-121

    Is long-term intravenous iron therapy risky?

  14. No Access

    Book Chapter

    Pages 123-128

    Anemia and erythropoietin therapy in kidney transplant recipients: where are the data?

  15. No Access

    Book Chapter

    Pages 129-138

    Intravenous iron treatment: a comparison of available drugs

  16. No Access

    Book Chapter

    Pages 139-140

    Epilogue

  17. Back Matter

    Pages 141-145